147 results about "Sulphonilamide" patented technology

The invention relates to N-hydroxysulfonamide derivatives that donate nitroxyl (HNO) under physiological conditions and are useful in treating and/or preventing the onset and/or development of diseases or conditions that are responsive to nitroxyl therapy, including heart failure and ischemia/reperfusion injury. Novel N-hydroxysulfonamide derivatives release NHO at a controlled rate under physiological conditions, and the rate of HNO release is modulated by varying the nature and location of functional groups on the N-hydroxysulfonamide derivatives.

The invention discloses a method for synthesizing perfluoroalkyl sulfimide alkali metal salt (M[Rf1SO2NSO2Rf2]) which is abbreviated to M[PFSI], wherein Rf1 and Rf2=CmF2m+1, m=1-8, M=Li, Na, K, Rb, and Cs. The method utilizes potassium (rubidium and cesium) salt of perfluoroalkyl sulfamide and perfluoroalkyl sulfonyl fluoride for reaction in the existence of potassium carbonate (rubidium and cesium), so that the potassium (rubidium and cesium) salt of the perfluoroalkyl sulfimide can be conveniently prepared with high yield which is 70-90%; the high-purity corresponding lithium (or sodium) salt (M[PFSI], M=Li and Na) can be obtained through double decomposition exchange reaction of the potassium (rubidium and cesium) salt and lithium perchlorate (or sodium) in aprotic polar solvent (such as acetonitrile, dimethyl carbonate, nitromethane and the like); and the hydrophobic functionalized ionic liquid composed of cations of sulfonium, ammonium or phosphorus with the [PFSI] through reaction of the prepared alkali metal salt and the sulfonium salt, ammonium salt or phosphorus salt of which the side chain contains functionalized functional groups.

The invention discloses sinomenine derivatives, and a preparation method and application thereof. The sinomenine derivatives are sinomenine derivative monomers or dimers formed by connecting the 4-position or 6-position carbon (C) of the frameworks of sinomenine and the conventional sinomenine derivatives with linker through X, wherein X is an ether bond, an ester bond, an amido bond, a sulfamide bond, or an amine bond and the like, and the linker is an aliphatic compound, an aromatic compound or polyethylene glycol and the like. The method for preparing the sinomenine derivatives is novel and unique, and simple and practicable; the prepared sinomenine derivatives have high purity and yield; when macrophages RAW264.7 in vitro are adopted to evaluate the NO inhibiting activity and anti-inflammatory action in rats, the sinomenine derivatives have high bioactivity, can be applied to preparing anti-inflammatory medicines for rheumatoid arthritis, rheumatic arthritis and the like, immunosuppressive agents and health products, have wide application range and good treatment effect, and have good social benefit.

There is provided a compound of Formula (I) wherein (I) R2 is selected from (i) an alkyloxyalkyl group (ii) a nitrile group, and wherein R2 is capable of forming a hydrogen bond (iii) alkylaryl group, wherein the aryl group is substituted by other than a C1-10 group (iv) alkenylaryl group wherein the aryl group is substituted (v) alkylheteroaryl group, wherein when heteroaryl group comprises only C and N in the ring, the aryl group is substituted by other than a methyl group (vi) alkenylheteroaryl group, (vii) ═N—O-alkyl or ═N—O—H group (viii) branched alkenyl (ix) alkyl-alcohol group (x) amide or alkylamide wherein (a) the alkyl of the alkylamide is —CH2— or —Ch2Ch2—, (b) the amide is di-substituted and/or (c) the amide is substituted with at least one of alkyl heterocycle group, alkenyl heterocycle group, alkylheteroaryl group, alkenylheteroaryl group, heteroaryl group, alkylamine group, alkyloxyalkyl group, alkylaryl group, straight or branched alkyl group, (xi) —CHO so that R1 together with R3 provide the enol tautomer (a); OR R2 together with R3 form (xii) a pyrazole wherein (a) R4 is ═N—O-alkyl or ═N—O—H group, (b) the pyrazole is substituted with one of alkyl-OH group, alkyl ester group, alkyloxyalkyl group, branched alkyl group, and an amide and/or (c) the 2 position is substituted with a group selected from —OH and —O-hydrocarbyl (xiii) a heteroaryl ring to provide a compound of the formula (b); (II) R2 is selected from groups capable of forming a hydrogen bond, a sulphamate group, a phosphonate group, a thiophosphonate group, a sulphonate group and a sulphonamide group; and (III) R3 is selected from —OH, ═O, or a C(═O)—mimetic.

The invention relates to a preparation method for celecoxib, and belongs to the field of chemical pharmaceuticals. The method comprises the step of performing cyclization reaction on 4, 4, 4-trifloro-1-(4-tolyl)-1, 3-butanedione and p-sulfamine phenylhydrazine or 4-sulfamine phenylhydrazine hydrochloride in a solvent to obtain a celecoxib coarse product, wherein the solvent for cyclization reaction is a low molecular organic acid or a low molecular organic acid aqueous liquor. According to the method, the product is high in yield, good in purity, easy to purity, good in quality and low in cost; and the method is environment-friendly in condensation process, and is suitable for large-scale industrial production.

The invention discloses a preparation method of azacyclo. The preparation method comprises the following steps of: (1) reacting diethylenetriamine or triethylene tetramine with methylsulfonyl chloride to generate methanesulfonamide; (2) during two-phase reaction, cyclizing compound catalytic cyclization on methanesulfonamide and a compound having the structure shown in a chemical formula (a) under the composite catalysis of benzyl triethylanmine compound and 15-crown-5 at 90 DEG C under a backflow condition; and (3) removing methylsulfonyl from methanesulfonamide azacyclo and performing methylation treatment, wherein X represents bromine, iodine or sulphonate. The preparation method has the advantages that raw materials are low in cost, atom economy is high, and operation is easy and safe. The preparation method is suitable for industrial production.

The invention provides a combination of polyethylene glycol and tamsulosin and a pharmaceutical compound comprising the combination which is as shown in a general formula (II). In the combination, a P and a P' are H or polyethylene glycol, and the P and the P' cannot be the H at the same time. The tamsulosin structurally contains a sulfamide group, the low-molecular-weight polyethylene glycol is introduced through an alkylation reaction, and therefore hydrophobicity of the tamsulosin is lowered, hydrophilism of the tamsulosin is increased, and the blood-brain barrier permeability of the tamsulosin is lowered. Therefore, the toxicity of the tamsulosin is lowered.

The invention relates to a novel method for synthesizing 2-ethoxycarbonylaminosulfonyl-N, N-dimethyl nicotinamide. 2-ethoxycarbonylaminosulfonyl-N,N-dimethyl nicotinamide is prepared by the following steps of taking liquid alkali as an acid binding agent; performing reaction of 2-aminosulfamide-N,N-dimethyl nicotinamide and ethyl chloroformate; adding 2-aminosulfamide-N,N-dimethyl nicotinamide into an acetone aqueous solution, adding ethyl chloroformate and liquid alkali into acetone aqueous solution while stirring; preserving heat till the completion of the reaction, distilling and recyclingacetone; filtering; separating; and drying to obtain the finished product. The product prepared by the method saves energy and reduces consumption and achieves the environmental safety; no pollutantssuch as carbon dioxide and salt-containing waste water are generated; and the yield and the content of the 2-ethoxycarbonylaminosulfonyl-N,N-dimethyl nicotinamide is high.

The invention discloses a sulfonic acid dimeric surfactant based on perfluorononylene and perfluorohexylene, and a preparation method of the surfactant. The surfactant is a compound with a general formula as described in the specification. As perfluor alkene oxygen phenyl serves as a lipophilic group, sulphonate serves as a hydrophilic group, and a lipophilic part is connected with a hydrophilic part by a sulfonamide bond, the surfactant is very high in surface activity and lower in critical micelle concentration. The preparation method takes the perfluorononylene or the perfluorohexylene as a raw material, and comprises the steps of condensing with phenol, chlorosulfonation, diamine condensing, and sulphur alkylation condensing. The preparation method has the characteristics of simple process, lower cost and the like, and has good application prospects.

The invention provides a rubber sealing ring. The material used by the rubber sealing ring is prepared from the following raw materials, in parts by weight: 80-90 parts of nitrile rubber; 5-7 parts of zinc oxide; 1-3 parts of an anti-aging agent; 0.5-1.5 parts of stearic acid; 90-110 parts of a high abrasion resistant carbon black; 2-4 parts of MDC sulphur; 0.5-1.5 parts of an accelerant; and 1-3 parts of N-cyclohexyl-2-benzothiazolesulfenamide. The rubber sealing ring provided by the invention can meet indicators stated by an SH/T0305-93 standard test method, and increases sealing performance in rubber seal adaptability tests of related petroleum products.

The present invention is based on the surprising finding that the linker employed in a bioconjugate, such as an anti-body-drug conjugate, is not therapeutically inert but has an effect on the therapeutic index of the bioconjugate. The present invention thus concerns a method for increasing the therapeutic index of a bioconjugate and the bioconjugates for use in treatment, in particular cancer. The bioconjugates according to the invention have a sulfamide linker comprising a group according to formula (1).

The invention provides a sulfanilamide micromolecule surface modified polyamide composite membrane and a preparation method thereof. The polyamide composite membrane comprises an ultra-filtration bottom membrane and a micromolecule modified polyamide layer, the polyamide layer covers the surface of the ultra-filtration bottom membrane, and functional groups of the small molecules are amino and sulfamido. According to the sulfanilamide micromolecule surface modified polyamide composite membrane, easily available functional micromolecule monomers with amino and sulfanilamide functional groups are grafted to the surface of the polyamide composite membrane through a secondary interface polymerization method to obtain a modified membrane, the hydrophilicity of the surface of the membrane is improved by utilizing the hydrophilicity of sulfanilamide groups, so that the mass transfer of water molecules is accelerated, the purposes of high flux and pollution resistance are achieved, and the water flux of the modified membrane can be increased by 38-65% compared with that of an unmodified polyamide membrane on the premise of keeping high rejection rate; and in addition, the existence of thesulfonamide groups provides more active N-chloro groups, so that the active chlorine resistance of the polyamide composite membrane is also improved.

The invention provides dihydrothiazolone compounds containing sulfamide, represented by a formula (I), pharmaceutical compositions and use thereof. The compounds can be combined with proteins with bromodomain structural domains so as to adjust a downstream signal channel and exert a special function, and can be used for treating many diseases associated with bromodomain structural domains. The compounds can interfere combination of Brd4 with the bromodomain structural domain and an acetylized histone so as to down-regulate transcription of a cancer gene c-myc and associated target genes thereof, so that the compounds can become effective therapeutic drugs for treating tumors.

The invention discloses an application of benzene-sulfamide compounds in preparing an anti-HIV-1(human immunodeficiency virus-1) drug. A general formula of the benzene-sulfamide compounds is as shown in the specification, wherein X1-X4 are independently selected from halogen, H and -NO2, and have one -NO2 at the same time at most; X1-X4 are not halogen at the same time; R1 is selected from the substances as shown in the specification, wherein Y is C or N, n is an integer of 2-6, R3 is H or a statured chain hydrocarbon or a cyclic hydrocarbon with carbon number not exceeding 5, R4 is H or saturated chain hydrocarbons of C1-C4; R2 is selected from H, halogen or substance as shown in the specification; Y1 and Y2 are independently selected from H, halogen, and methyl. By applying the binding characteristic of Rev-RRE (response element), the inventor proves that the benzene-sulfamide compounds with the general formula can restrain Rev protein activity, causes expression quantity of luciferase in a screening system to reduce, and has a good antiviral effect. Moreover, powerful theoretical basis and practice basis are provided for further developing the antiviral drug, and therefore, the application has important development value and development significance.

The invention belongs to the technical field of organic synthesis, and concretely discloses a method for preparing pyrazole sulfamide type sodium, potassium and calcium metal complexes by an ultrasonic wave one-pot method and application. Pyrazolone ring amidogen is subjected to structure modification and solvent participation; a series of pyrazole sulfamide type sodium, potassium and calcium metal complexes are synthesized by the ultrasonic wave one-pot method. The metal coordination modes of sodium, potassium, calcium and the like are diversified; the coordination with nitrogen atoms and oxygen atoms on sulfamide is realized; the coordination with oxygen atoms on a solvent can also be realized; metal on the potassium complex can also be coordinated with halogen atoms on substitutional groups; the synthetized sulfamide type metal complexes based on a pyrazole framework have excellent biological activity; particularly, high activity is shown in the insect killing and antibiosis aspects, so that the synthetized sulfamide type metal complexes based on the pyrazole framework have great research and development and application values.

The invention relates to the field of medicinal chemistry and pharmacotherapeutics, particularly to a compound represented by a general formula (I), a pharmaceutically acceptable salt, a prodrug molecule and a mixture thereof, a preparation method of the compound, a pharmaceutical composition containing the compound, and applications as an FABP4/FABP5 double-targeting inhibitor. The invention relates to applications of an aryl sulfamide compound in treatment of metabolic diseases and autoimmune diseases.

The invention includes an improved process for producing tamsulosin comprising reacting 5-(2-aminopropyl)-2-methoxybenzenesulfonamide with 2-(o-ethoxyphenoxy)ethyl bromide in an organic phosphite solvent to obtain tamsulosin. Optically pure (R)-5-(2-aminopropyl)-2-methoxybenzenesulfonamide can be employed to produce optically pure (R)-tamsulosin product. The organic phosphite solvent utilized in the reaction can include tri-alkyl phosphites such as triethyl phosphite, trimethyl phosphite, and tributyl phosphite. Additionally, processes for producing tamsulosin having a low concentration of by-product contaminants, such as 5-((R)-2-{Bis-[2-(2-ethoxyphenoxy)ethyl]amino}-propyl)-2-methoxybenzenesulfonamide, and the use of such by-products to monitor the chemical purity of tamsulosin, are provided.